Rhodium(III) analogues of antitumour-active ruthenium(III) compounds: The crystal structure of [ImH][trans-RhCl4(Im)2] (Im=imidazole)

Antitumor pentamethylcyclopentadienyl rhodium complexes of maltol and allomaltol: Synthesis, solution speciation and bioactivity

“…The anticancer properties of RhCl 3 have been known for many decades [10]. Simple complexes such as mer-[RhCl 3 (NH 3 ) 3 ] or mer,cis-[RhCl 3 (DMSO) 2 (NH 3 )] were also found to be anticancer active in vivo [11,12]. Various dirhodium(II,II) complexes have also been reported by Dunbar et al such as carboxylates which are able to inhibit cell viability of the human cancer cells and DNA was found to be their cellular target via the potentially intercalation forming DNA interstrand cross-links [13,14].…”

Cell‐Selective, Apoptosis‐inducing Rhodium(III) Crown Thiaether Complexes

“…[1] The majority of interest has focused on dirhodium(II,II) tetracarboxylates of the type [Rh 2 L 2 (RCOO) 4 ] (R= alkyl group; L = H 2 O or another monodentate ligand), [2][3][4] but recent reports have suggested that octahedral chloridorhodium(III) complexes may offer considerable potential as anticancer agents. For instance, mer,cis-[RhCl 3 -(DMSO) 2 (NH 3 )] exhibits promising cytotoxicity towards human ovarian (A2780) and colon carcinoma (LoVo) cell lines, [5] while polypyridyl (pp) complexes of the type mer-[RhCl 3 (DMSO)(pp)] are potent antitumor agents used in the treatment of lymphoma and leukemia. [6] In vitro IC 50 values of the latter type of compounds are strongly dependent on the size of the chelating polypyridyl ligand within the series: pp = bpy, phen, dpq (bpy = 2,2'-bipyridyl; phen = 1,10 phenanthroline; dpq = dipyrido[3,2-f:2',3'-h]quinoxaline).…”

“…We have, therefore, further characterized their structure-activity relationships, with the aim of establishing lead substances, by studying the cell death-inducing properties of novel types of ( [9] 2+ , where pp = bpy, phen, dpq, dppz, bpm, tap (5)(6)(7)(8)(9)(10). [13] The most active substances from the series 1-10 were selected for comparative cytotoxicity studies against BJAB lymphoma and leukocyte cells from healthy patients, to establish whether these lead complexes exhibit adequate cell selectivity to justify further investigation.…”

New Chlorido(dimethyl sulfoxide)iridium(III) Complexes with N6‐Substituted Adenines – Kinetic N(7) versus Thermodynamic N(9) Coordinated Adenine Isomers

“…[16][17][18] Moreover, several Ir III -and Rh III -related compounds have proved to be potent in vitro cytotoxic agents, [19,20] although similar "NAMI-A"-Ir III or Rh III complexes have been found to be inactive, [11,12,21] which has been related to the lack of lability for ligand substitution and redox properties of the metal centre. In this way, the more inert Ir III compounds could be useful as trace systems to study the route of Ru III analogues or designed complexes to deliver an active ligand to a specific receptor.…”